Advanced Solid Tumor Clinical Trial
Official title:
A Phase 1/2, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10370 Monotherapy in Patients With Advanced Solid Tumors
HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.
Status | Recruiting |
Enrollment | 176 |
Est. completion date | April 30, 2026 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for participation in this study: 1. Men or women greater than or equal to 18 years 2. Locally advanced or metastatic cancer patients confirmed by histology or cytology, for which standard treatment is invalid, unavailable or intolerable 3. Pathological, tumor tissue samples can be used to test KRAS G12C mutation by central laboratory for Phase 1b subjects. 4. At least one measurable lesion in accordance with RECIST 1.1 5. Eastern Cooperative Oncology Group (ECOG) performance status: 0~1 6. Estimated life expectancy >12 weeks 7. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit. 8. Females must have the evidence of non-childbearing potential 9. Signed and dated Informed Consent Form Exclusion Criteria: 1. Treatment with any of the following: 1. Previous or current treatment with KRAS G12C inhibitors 2. Any cytotoxic chemotherapy, anticancer Chinese medicine and targeted small molecule inhibitors within 14 days of the first dose of HS-10370 3. Any investigational agents and large molecule antibodies within 28 days of the first dose of HS-10370 4. Local radiotherapy for palliation within 2 weeks of the first dose of HS-10370, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose of HS-10370 5. Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of HS-10370 2. Inadequate bone marrow reserve or serious organ dysfunction 3. Uncontrolled pleural, ascites or pericardial effusion 4. Known and untreated, or active central nervous system metastases 5. Active autoimmune diseases or active infectious disease 6. Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications 7. History of hypersensitivity to any active or inactive ingredient of HS-10370 or to drugs with a similar chemical structure or drugs belonging to the same category of HS-10370 8. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator 9. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator 10. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study 11. History of neuropathy or mental disorders, including epilepsy and dementia |
Country | Name | City | State |
---|---|---|---|
China | Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase Ia:To determine the maximum tolerated dose (MTD) | Number of participants with dose limiting toxicity | From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (28 days). | |
Primary | 2. Phase Ib/II: To evaluate clinical activity/efficacy of HS-10370 by assessment of objective response rate | Objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) | up to 24 months | |
Secondary | Incidence and severity of treatment-emergent adverse events | Number of participants with treatment related adverse events. | From baseline until 28 days after the last dose | |
Secondary | Observed maximum plasma concentration (Cmax) after single dose of HS-10370 | In the study of single-dose, Cmax will be obtained following administration of a single oral dose of HS-10370 on Day 1 to Day 6 | From pre-dose to 120 hours after single dose on Day 1 | |
Secondary | Time to reach maximum plasma concentration (Tmax) after single dose of HS-10370 | In the study of single-dose, Tmax will be obtained following administration of a single oral dose of HS-10370 on Day 1 to Day 6. | From pre-dose to 120 hours after single dose on Day 1 | |
Secondary | Apparent terminal half-life (T1/2) after single dose of HS-10370 | Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by ?z. | From pre-dose to 120 hours after single dose on Day 1 | |
Secondary | Duration of response (DOR) | DOR assessed by RECIST 1.1 criteria | 24 months | |
Secondary | Disease Control Rate (DCR) | DCR assessed by RECIST 1.1 criteria | 24 months | |
Secondary | Progression-free survival (PFS) | PFS assessed by RECIST 1.1 criteria | 24 months | |
Secondary | Overall survival (OS) | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT05508100 -
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05515185 -
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
|
Early Phase 1 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT02836600 -
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04890613 -
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06007482 -
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04108676 -
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05076396 -
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06054932 -
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06008366 -
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04825392 -
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06365918 -
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
|
Phase 1 | |
Recruiting |
NCT05569057 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05461287 -
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05443126 -
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
|
Phase 1/Phase 2 |